Consistent with their mission to prioritize clinical convenience, practicality, and effectiveness, numerous considerations were incorporated into the design of their product lines. From the packaging, to the shape configurations, all relate to optimizing suitability for use and potential for clinical benefit. But, FIRST AND FOREMOST, its products were developed with design requirements for safety, and products provided for distribution are verified to satisfy these requirements.
What sets Seed Biotech apart is its process. They use precise methods to get measurable results and create better biologic products. Their proprietary decellularization process demonstrates a greater than 95% reduction in DNA.
Under the guidance of clinical and industry experienced experts, Seed Biotech’s core competency is based on a novel decellularization and stabilization process conducted in a quality by-design facility with advanced operational support systems.
Seed Biotech is uniquely able to optimally prepare highly variable biological materials through a dynamic purification process that depletes biomaterials of cells and cellular contents without imparting unintentional alterations to the extracellular matrix comprised of soluble and non-soluble bioactive constituents. This technology uniquely positions Seed Biotech as an industry leader in innovation and a manufacturer of high-quality products.
Wounds
Monitoring the speed of the wound healing process is crucial for improving patient outcomes. Research highlights the significance of achieving at least 53% wound closure within the first 30 days, as failure to do so diminishes the likelihood of complete healing within twelve weeks. This underscores the vital role of safe and effective regenerative therapies in supporting the body's ability to resolve chronic wounds. [1]
The physiology of wound healing is comprised of four overlapping stages.
Chronic Wounds
Chronic wounds, unlike their acute counterparts, defy the body’s natural healing processes. These persistent sores, ulcers, or injuries linger for weeks, months, or even years. Their stubbornness challenges patients, caregivers, and healthcare providers alike.
From diabetic foot ulcers to pressure sores, venous leg ulcers to non-healing surgical wounds, the journey from acute to chronic is fraught with complexities.
Research suggests that symptoms that meet the criteria below may respond to adding Regenerative Therapies to the Standard of Care. [2]
Possessing a comprehensive inventory of essential tools for chronic wound care, coupled with precise application and consistent timing of use, may help facilitate wound closure.
[1]. Frykberg RG, Banks J. Challenges in the Treatment of Chronic Wounds. Adv Wound Care (New Rochelle). 2015 Sep 1;4(9):560-582. doi: 10.1089/wound.2015.0635. PMID: 26339534; PMCID: PMC4528992
[2]. Journal of Foot and Ankle Research - 2022 - Mohammed - Human amniotic membrane products for patients with diabetic foot
RingBack Request
